Truist Cuts Alnylam Pharmaceuticals to Hold From Buy
Truist Securities lowered its rating on Alnylam Pharmaceuticals to Hold from Buy.
Related stories
VCIG: Nasdaq trading halt continues — volatility pause (3:16 PM ET)
Nasdaq kept trading halted in VCIG (volatility pause) at 3:16 PM ET.
M impact | EQUITY | Nov 02, 2026, 08:35 PM UTC
Pendant Power acquires shares in PLC
Pendant Power acquired shares in PLC on November 2, 2026.
M impact | EQUITY | Nov 02, 2026, 08:21 PM UTC
Alicorp Acquires Flora Food Group
Alicorp acquired Flora Food Group, expanding its presence in the spreads category with brands including Dorina and La Danesa.
M impact | EQUITY | Nov 02, 2026, 08:14 PM UTC
Fortinet Shares Hit 22-week Low
Fortinet shares decreased to 127.33 USD, the lowest since May 2026. Over the past 4 weeks, Fortinet lost 30.79%, and in the last 12 months, it increased 45.6%.
L impact | EQUITY | Nov 02, 2026, 08:12 PM UTC
FB Financial Reports Third-Quarter 2026 Results
FB Financial reported revenue of $174.5 million, up 0.4% year over year. Net income rose to $60.2 million from $23.4 million, and diluted EPS increased to $1.20 from $0.43. Lower c
M impact | EQUITY | Nov 02, 2026, 08:11 PM UTC
Federal Signal Publishes Q3 2026 Earnings Call Transcript
M impact | EQUITY | Nov 02, 2026, 08:09 PM UTC